



FDA CLEARANCE RECEIVED FOR HEART ATTACK STEM CELL CLINICAL TRIAL

Platform stem cell technology now in two major US- based trials

Key points:

- US FDA clears IND submission by Angioblast Systems Inc. to begin heart attack clinical trial
- First FDA-cleared allogeneic (unrelated recipient or 'off-the-shelf') stem cell product to begin catheter delivery for heart attack clinical trials
- The company's platform technology is now in two US-based Phase II clinical trials for significantly different indications.

New York, New York; 2 May 2007: Angioblast Systems Inc. announces that the United States Food and Drug Administration (US FDA) has cleared the Investigational New Drug Submission (IND) to commence a Phase 2 clinical trial of its allogeneic, or 'off-the-shelf', adult stem cells for patients with heart attacks.

"FDA clearance is a significant step towards commercialising our stem cell products in the US, the world's largest market for cardiovascular diseases," said founder and Chief Scientific Adviser, Professor Silviu Itescu.

"Importantly FDA clearance was obtained within 30 days of the submission of the IND," he said.

The Phase 2 clinical trial will be based at the Texas Heart Institute, and will follow a similar protocol to the one used by the same investigators in preclinical studies for the IND submission. These showed that implantation of the company's proprietary allogeneic stem cells by catheter into damaged heart muscle resulted in significant improvement in heart function and reduction in congestive heart failure.

This clinical trial will be the first to test an allogeneic stem cell product injected by catheter into heart muscle damaged by a recent heart attack. The trial will use the latest generation catheters provided through Angioblast's ongoing relationship with the Johnson & Johnson companies, Cordis Corporation and Biosense Webster.

The commercial strategy is to generate high margin stem cell products that are obtained from a single donor, expanded, frozen, and subsequently used in thousands of unrelated, or allogeneic, recipients at the time and place of need.

Over one million new patients with heart attacks are treated annually in the US alone, representing a multi-billion dollar market opportunity. Current therapies do not result in rebuilding of heart muscle, and do not prevent progression of congestive heart failure, poor quality of life, and long-term deterioration.

The clinical trial design was announced on 2 April 2007.

About Angioblast Systems, Inc.

Angioblast Systems, Inc. is an American company developing the platform MPC technology for the treatment of cardiovascular diseases, including repair and regeneration of blood vessels and heart muscle.

For further information, please contact:

Michael Schuster, MS, MBA

Director of Business Development

Angioblast Systems, Inc.

T: 1-212-880-2060

E: Michael.schuster@angioblast.com

W: www.angioblast.com